IL314916A - Bispecific CD28 antibodies for targeted T cell activation - Google Patents

Bispecific CD28 antibodies for targeted T cell activation

Info

Publication number
IL314916A
IL314916A IL314916A IL31491624A IL314916A IL 314916 A IL314916 A IL 314916A IL 314916 A IL314916 A IL 314916A IL 31491624 A IL31491624 A IL 31491624A IL 314916 A IL314916 A IL 314916A
Authority
IL
Israel
Prior art keywords
targeted
cell activation
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
IL314916A
Other languages
English (en)
Hebrew (he)
Inventor
Sara Majocchi
Krzysztof Masternak
Limin Shang
Nicolas Fischer
Xavier Chauchet
Original Assignee
Novimmune Sa
Sara Majocchi
Krzysztof Masternak
Limin Shang
Nicolas Fischer
Xavier Chauchet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Sara Majocchi, Krzysztof Masternak, Limin Shang, Nicolas Fischer, Xavier Chauchet filed Critical Novimmune Sa
Publication of IL314916A publication Critical patent/IL314916A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL314916A 2022-03-07 2023-03-07 Bispecific CD28 antibodies for targeted T cell activation IL314916A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317491P 2022-03-07 2022-03-07
US202263323893P 2022-03-25 2022-03-25
PCT/IB2023/000124 WO2023170474A1 (en) 2022-03-07 2023-03-07 Cd28 bispecific antibodies for targeted t cell activation

Publications (1)

Publication Number Publication Date
IL314916A true IL314916A (en) 2024-10-01

Family

ID=86272440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314916A IL314916A (en) 2022-03-07 2023-03-07 Bispecific CD28 antibodies for targeted T cell activation

Country Status (8)

Country Link
US (1) US20240002544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490192A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508066A (cg-RX-API-DMAC7.html)
CN (1) CN119233993A (cg-RX-API-DMAC7.html)
AU (1) AU2023232992A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249273A1 (cg-RX-API-DMAC7.html)
IL (1) IL314916A (cg-RX-API-DMAC7.html)
WO (1) WO2023170474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512574A (ja) * 2021-03-22 2024-03-19 ノビミューン エスアー Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
AU2023362569A1 (en) * 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2025051895A1 (en) * 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
TW202544034A (zh) * 2024-05-06 2025-11-16 美商榮都醫療公司 結合至cd28及nectin-4之雙特異性抗體
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006050949A2 (de) 2004-11-11 2006-05-18 Tegenero Ag Superagonistische anti-cd28 antikörper
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US11260117B2 (en) * 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
WO2019016411A1 (en) * 2017-07-21 2019-01-24 Novimmune Sa GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE
CN112566938B (zh) * 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
CN119143875A (zh) 2018-06-21 2024-12-17 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
KR20210104836A (ko) 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
WO2020132024A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
EP3941941A1 (en) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CR20220627A (es) 2020-06-23 2023-02-17 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
KR20230121772A (ko) * 2020-12-18 2023-08-21 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이적 항체

Also Published As

Publication number Publication date
CA3249273A1 (en) 2023-09-14
US20240002544A1 (en) 2024-01-04
WO2023170474A1 (en) 2023-09-14
AU2023232992A1 (en) 2024-08-15
EP4490192A1 (en) 2025-01-15
JP2025508066A (ja) 2025-03-21
CN119233993A (zh) 2024-12-31

Similar Documents

Publication Publication Date Title
IL276975A (en) Chimeric antigen receptor cell immunotherapy with a bispecific antibody
IL286536A (en) Multispecific egfr x cd28 antibodies
IL320152A (en) Bispecific antibodies against PD-L1 and CD28 for immune checkpoint-dependent T cell activation
IL291186A (en) Bispecific antibody chimeric antigen receptor cell immunotherapy
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EP4410965A4 (en) T LYMPHOCYTE PRODUCTION PROCESS
IL288965A (en) A method for generating a multivalent bispecific antibody-expressing cell using a targeted combination of multiple expression cassettes in a defined organization
PT4157876T (pt) Anticorpos anti-pd-1
IL288967A (en) A method for generating a bispecific bivalent antibody-expressing cell using a targeted combination of multiple expression cassettes in a defined organization
CA3258462A1 (en) VARIANT ANTIBODIES THAT BIND TO GAMMA-DELTA T LYMPHOCYTE RECEPTORS
CA3261147A1 (en) DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
EP4048700A4 (en) BISPECIFIC ANTI-BCMA/ANTI-4-1BB ANTIBODIES AND THEIR USES
IL321509A (en) CD28/OX40 bispecific antibodies
IL319891A (en) Anti-CD28 antibodies
CA3260186A1 (en) Formulations for Bispecific Antibodies: Anti-PD-L1/Anti-4-1BB
WO2014132131A3 (en) In situ affinity maturation of antibodies
CA3271184A1 (en) Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
HK40131732A (zh) Cd28/ox40双特异性抗体
CA3277184A1 (en) Cd28/ox40 bispecific antibodies
IL315451A (en) Methods for the purification of bispecific antibodies
HK40116564A (en) Methods for purifying bispecific antibodies
HK40082085A (en) Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
IL320411A (en) ANTI-CD3 antibodies
HK40101272A (en) Antibodies that bind gamma-delta t cell receptors
CA3289016A1 (en) Anti-cd28 x anti-trop2 antibodies